Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Natalia Voronkova"'
Publikováno v:
Bulletin of KSAU. :11-17
Autor:
Heiner Wedemeyer, Katrin Schöneweis, Pavel Bogomolov, Antje Blank, Natalia Voronkova, Tatiana Stepanova, Olga Sagalova, Vladimir Chulanov, Marina Osipenko, Viacheslav Morozov, Natalia Geyvandova, Snezhana Sleptsova, Igor G Bakulin, Ilsiyar Khaertynova, Marina Rusanova, Anita Pathil, Uta Merle, Birgit Bremer, Lena Allweiss, Florian A Lempp, Kerstin Port, Mathias Haag, Matthias Schwab, Julian Schulze zur Wiesch, Markus Cornberg, Walter E Haefeli, Maura Dandri, Alexander Alexandrov, Stephan Urban
Publikováno v:
The Lancet. Infectious diseases. 23(1)
Bulevirtide is a first-in-class peptidic entry inhibitor for hepatitis B virus (HBV) and hepatitis D virus infection. In July, 2020, bulevirtide 2 mg received conditional marketing authorisation by the European Medical Agency for treatment of chronic
Publikováno v:
Proceedings of the International Scientific Conference The Fifth Technological Order: Prospects for the Development and Modernization of the Russian Agro-Industrial Sector (TFTS 2019).
Publikováno v:
Proceedings of the International Scientific Conference The Fifth Technological Order: Prospects for the Development and Modernization of the Russian Agro-Industrial Sector (TFTS 2019).
Autor:
Florian A. Lempp, Ksenia Y. Kokina, Antje Blank, Matthias Schwab, Maria Macievich, Thorsten Lehr, Natalia Voronkova, A. Alexandrov, Walter E. Haefeli, Maria Petrachenkova, Stephan Urban, Heiner Wedemeyer, Pavel O. Bogomolov, Mathias Haag
Publikováno v:
Journal of Hepatology. 65:490-498
Background & Aims The therapeutic option for patients with chronic hepatitis delta virus infection (CHD) is limited to interferon alpha with rare curative outcome. Myrcludex B is a first-in-class entry inhibitor inactivating the hepatitis B virus (HB
Autor:
D. V. Dubodelov, Kuzin Sn, E. N Kudryavtseva, O. S. Kuz'mina, I. M. Korabelnikova, Lavrov Vf, V. M. Matsievich, Semenenko Ta, Natalia Voronkova, P. O. Bogomolov
Publikováno v:
Эпидемиология и вакцинопрофилактика, Vol 15, Iss 2, Pp 11-18 (2016)
The structure of HCV genotypes/subtypes and dynamics of its changes in a cohort of adult patients with chronic hepatitis C (n = 17229) was studied during 2008-2015 in the Moscow region. The prevalence of subtypes 1b and 3A HCV, whose relative density
Autor:
O. S. Kuz'mina, Natalia Voronkova, K. Yu. Kokina, Alexey O. Bueverov, Pavel O. Bogomolov, M. V. Matsievich
Publikováno v:
Almanac of Clinical Medicine. :126-131
Autor:
T. N. Sheshukova, O. V. Uvarova, S. V. Ivannikova, L. S. Gorbunova, M. N. Trofimova, I. N. Azarova, K. Yu. Kokina, Alexey O. Bueverov, E. M. Kondratenko, E. N. Cherenkova, O. A. Kudrya, S. V. Koblov, I. M. Shilkina, I. N. Kovalev, M. Yu. Petrachenkova, Pavel O. Bogomolov, M. V. Matsievich, S. I. Kiyan, Natalia Voronkova, G. G. Chernyavskaya, Yu. Yu. Gumerova, O. S. Kuz'mina, V. D. Beznosenko, E. V. Fedosova, E. N. Kudryavtseva, G. V. Sadovskaya, N. A. Gorshilina, N. V. Kosheleva, V. A. Sinitsyna, M. L. Samsonyan
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 0, Iss 40, Pp 48-57 (2016)
Background: The beginning of a new era of direct acting antivirals sets up its own rules, that is, to achieve the highest efficacy with the shortest duration of treatment. It is assumed that the use of the first generation of direct acting antivirals
Autor:
Vladimir Chulanov, Sandra Ciesek, Maura Dandri, Ulf Dittmer, Tatyana Stepanova, Stephan Urban, Heiner Wedemeyer, Jürgen Burhenne, Birgit Bremer, A. Alexandrov, Pavel O. Bogomolov, Natalia Voronkova, Walter-Emil Haefeli, Katrin Schöneweis, Lena Allweiss
Publikováno v:
Journal of Hepatology. 70:e81
Autor:
Antje Blank, Natalia Voronkova, Julian Schulze Zur Wiesch, Stephan Urban, Jürgen Burhenne, A. Alexandrov, Walter-Emil Haefeli, Birgit Bremer, Matthias Schwab, Anita Pathil, Katrin Schöneweis, H. Wedemeyer, M. Dandri-Petersen, Pavel O. Bogomolov, Lena Allweiss, Mathias Haag
Publikováno v:
Journal of Hepatology. 68:S3